cancer immunology - sarcoma - melanoma - radiation oncology - https://xitter.cf/t.co/ZhHn8j94Nm @stanford
Los Angeles, CA
Joined May 2012
- Tweets282
- Following417
- Followers714
- Likes1.9K
Anusha Kalbasi retweeted
Excited to share our new study describing uRARE-seq, a tumor-naive #LiquidBiopsy method for analyzing urine cell-free RNA (cfRNA) in #BladderCancer and other genitourinary cancers. Out today in @NatureMedicine 🧵 1/16 rdcu.be/bRoXk7REWtRa
Anusha Kalbasi retweeted
How the hunt for human retroviruses led to the discovery of IL-2 and a path to immunotherapy
science.org/doi/10.1126/scie…
Anusha Kalbasi retweeted
Soft tissue sarcomas (#STS) have few recurrent mutations, making ctDNA testing a challenge. In our new paper in @JCO_ASCO, we show that personalized ctDNA analysis achieves high detection rates and can track treatment response in localized STS. 🧵 (1/11)
doi.org/10.1200/JCO-26-00769
Anusha Kalbasi retweeted
Highly anticipated data with first in class modified TIL therapy that does not use IL2, has lower dose lymphodepleting chemo - single arm ph1/2 OBX-115 in refractory metastatic melanoma #ASCO26 @DrBetofMDPhD @StanfordCancer
ORR 67% w 2 CR (!!)
DoR not reached (1+ to 14+m)
Anusha Kalbasi retweeted
SCI member @xrtcell & others show that combining targeted #RadiationTherapy with an experimental immune-boosting drug (BO-112) & anti-PD-1 therapy before surgery may help the immune system fight aggressive #SoftTissueSarcomas. brnw.ch/21x2SeG
Anusha Kalbasi retweeted
🚨What if we could reliably program macrophage polarization state?🚨
biorxiv.org/content/10.64898…
Macrophages are highly plastic immune cells that perform critical functions by polarizing into distinct cellular states. The polarization state of macrophages can substantially influences the progression of cancers, infections, and autoimmunity. (1/11)
Anusha Kalbasi retweeted
Thrilled to share the primary focus of my PhD thesis work, now out in @ScienceMagazine today!
We developed Trikines — engineered cytokines that reconfigure receptor complex assembly to reshape signaling directly in endogenous immune cells.
doi.org/10.1126/science.adx9…
Anusha Kalbasi retweeted
Two complementary studies from our group out today: a therapeutic peptide vaccine trial for fibrolamellar carcinoma (FLC) & TIRTL-Seq, our robust method for deep quantitative paired TCR sequencing a🧵w/ @MarkYarchoan & @pogorely nature.com/articles/s41591-0… & nature.com/articles/s41592-0…
Anusha Kalbasi retweeted
IL-9 enhancement of engineered CAR-T therapies
@ImmunityCP @carlhjune @msofiacastelli
@Penn @xrtcell @stanford @KaylaKulhanek
cell.com/immunity/fulltext/S…
cell.com/immunity/fulltext/S…
Anusha Kalbasi retweeted
Engineering T cells (CAR T) for treatment of solid cancers has had mixed success to date. Two reports today raise the promise of using interleukin-9 as a way to raise efficacy @ImmunityCP
cell.com/immunity/fulltext/S…
cell.com/immunity/fulltext/S…
Anusha Kalbasi retweeted
Please join us in congratulating our department chair, Quynh Le, MD, for receiving the 2025 @ASTRO_org Gold Medal Award. Dr. Le was awarded the Gold Medal during the ASTRO Annual Meeting Award Ceremony yesterday, September 30, 2025.
Anusha Kalbasi retweeted
Tumors often metastasize to lymph nodes before distant sites, yet evidence suggests that distant mets can originate from unique clones. Is this divergent seeding random? No. Check out our newest @biorxivpreprint to learn how the mechanisms diverge and how to harness them for IO.
I’m excited to share the first major story from my PhD today on the complex role of type 1 interferon in metastasis and immunotherapy!
This work was made possible with the support of @RetickerFlynn, Marcos Labrado, and the incredible protein engineer @grayerodriguez
Anusha Kalbasi retweeted
Congrats @Stef_Tst on this enormous effort! This was a fun collaboration with @xrtcell, and we are thankful to our awesome co-authors. Check out our web interface to find new cell tx targets using your own data or to explore ours in soft tissue sarcomas: scanact.stanford.edu
🚨Really excited to share the manuscript for SCAN-ACT, our computational pipeline built to aid in the identification of cellular therapy targets in solid tumors using single-cell transcriptomics!
🔗 scanact.stanford.edu
📄 doi.org/10.1186/s13073-025-0…
👇🧵 1/10 Summary:
Anusha Kalbasi retweeted
Amazing plasticity in T cells revealed through synthetic biology. Bold science spearheaded by my friend @YangZhao102 and co-led by @xrtcell and Chris Garcia. Huge congrats to Yang and the team!
Excited to share our @Nature papers exploiting the receptor pairing code to expand the cytokine receptor alphabet in T cells. Nonnatual receptors reprograms T cells into myeloid lineage. Grateful for the amazing collaborators @xrtcell , @MasatoOgishi
Anusha Kalbasi retweeted
Excited to share our @Nature papers exploiting the receptor pairing code to expand the cytokine receptor alphabet in T cells. Nonnatual receptors reprograms T cells into myeloid lineage. Grateful for the amazing collaborators @xrtcell , @MasatoOgishi
Anusha Kalbasi retweeted
🚨More cytokine-signaling magic from the @xrtcell and Garcia labs. Non-natural signal pairing with the common gamma chain receptor can drive unique transcriptional programs in T cells. 🤯This includes induction of phagocytic T cells by pairing with GSCFR!! rdcu.be/eACzg
Anusha Kalbasi retweeted
We are hiring @CUCancerCenter for #sarcoma faculty! Lots of patients, cutting edge clinical trials, a phenomenal multidisciplinary team, and all this with beautiful mountains to play in! DM me for details and feel free to share!
Anusha Kalbasi retweeted
We are thrilled to share that Everett Moding, MD, PhD, Assistant Professor of Radiation Oncology, has received a MERIT R37 Award from the NIH! This award is a long-term grant for investigators with outstanding research accomplishments and high productivity. Congratulations!
Anusha Kalbasi retweeted
BREAKING: We uncovered a potent immune alliance that could change how we treat solid tumors.
Published in @Cancer_Cell , we show that Th17 cells *must* work with B cells to eliminate tumors—and keep it from coming back.
📄 cell.com/cancer-cell/fulltex…
🧵1/12👇Let’s walk through it:
Anusha Kalbasi retweeted
Happy to share the final results of the 🇪🇸 & 🇫🇷 ph2 trial of intratumoral BO-112 + pembro for patients with anti PD-1 resistant #melanoma. 25% ORR and 54% patients alive at 2 years. 16 years of basic and clinical research behind. Some context here 👇🧵
ascopubs.org/doi/10.1200/JCO…
